hrcak mascot   Srce   HID

Acta Pharmaceutica, Vol. 63 No. 3, 2013.

Pregledni rad
https://doi.org/10.2478/acph-2013-0022

Drug interactions with statins

ANIDA ČAUŠEVIĆ-RAMOSEVAC ; Bosnalijek, Pharmaceutical and Chemical Industry, Joint Stock Company, Sarajevo, Bosnia and Herzegovina
SABINA SEMIZ ; Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina; Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Puni tekst: engleski, pdf (99 KB) str. 277-293 preuzimanja: 5.409* citiraj
APA 6th Edition
ČAUŠEVIĆ-RAMOSEVAC, A. i SEMIZ, S. (2013). Drug interactions with statins. Acta Pharmaceutica, 63 (3), 277-293. https://doi.org/10.2478/acph-2013-0022
MLA 8th Edition
ČAUŠEVIĆ-RAMOSEVAC, ANIDA i SABINA SEMIZ. "Drug interactions with statins." Acta Pharmaceutica, vol. 63, br. 3, 2013, str. 277-293. https://doi.org/10.2478/acph-2013-0022. Citirano 26.05.2019.
Chicago 17th Edition
ČAUŠEVIĆ-RAMOSEVAC, ANIDA i SABINA SEMIZ. "Drug interactions with statins." Acta Pharmaceutica 63, br. 3 (2013): 277-293. https://doi.org/10.2478/acph-2013-0022
Harvard
ČAUŠEVIĆ-RAMOSEVAC, A., i SEMIZ, S. (2013). 'Drug interactions with statins', Acta Pharmaceutica, 63(3), str. 277-293. doi: https://doi.org/10.2478/acph-2013-0022
Vancouver
ČAUŠEVIĆ-RAMOSEVAC A, SEMIZ S. Drug interactions with statins. Acta Pharm. [Internet]. 2013 [pristupljeno 26.05.2019.];63(3):277-293. doi: https://doi.org/10.2478/acph-2013-0022
IEEE
A. ČAUŠEVIĆ-RAMOSEVAC i S. SEMIZ, "Drug interactions with statins", Acta Pharmaceutica, vol.63, br. 3, str. 277-293, 2013. [Online]. doi: https://doi.org/10.2478/acph-2013-0022

Sažetak
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are generally very well tolerated as monotherapy. Statins are associated with two important, adverse effects, asymptomatic elevation in liver enzymes and myopathy. Myopathy is most likely to occur when statins are administered with other drugs. The statins are substrates of multiple drug transporters (including OATP1B1, BCRP and MDR1) and several cytochrome P450 (CYP) enzymes (including CYP3A4, CYP2C8, CYP2C19, and CYP2C9). Possible adverse effects of statins can occurr due to interactions with concomitant use of drugs that substantially inhibit or induce their methabolic pathway. This review will summarize the most important interactions of statins.

Ključne riječi
statins; drug interactions; cytochrome P450 (CYP) enzymes; drug transporters; adverse effects

Hrčak ID: 102048

URI
https://hrcak.srce.hr/102048

Posjeta: 5.782 *